Eurand NV’s affiliate, Eurand Pharmaceuticals Inc, has been granted an exclusive license by Chiesi Farmaceutici SpA for its gastro-resistant, controlled-release tablet formulation of the corticosteroid, beclomethasone dipropionate, in the U.S. and Canada. The gastro-intestinal product is currently approved and marketed in the U.K., Italy, Spain and Belgium. Eurand’s newly licensed product is as effective in treating Ulcerative Colitis and Crohn’s disease as classical corticosteroids, with relatively lower side effects.